Direction toward New Mid-term Plan
Terumo Corporation
President & Representative Director
Yutaro Shintaku
October 30, 2012

Direction toward New Mid-term Plan Aim to become a company w/ global presence¾

Won’t adopt a strategy in “long-term goal FIRST”- 1 trillion yen in 10yrs¾

Profitable & sustainable growth Key initiatives¾

Re-evaluate the business portfolio¾

Enrich “minimally invasive” new products pipeline¾

Enhance operational efficiency & global headquarter capability¾

China, Brazil, & India: Further business localization, Partnershipw/ local companies
2012/10/30©Terumo Corporation

2/6

Enrich “Minimally Invasive Treatment” Products Pipeline
 So far good progress on launching products¾ Steadily launching growth driver products for current mid-term plan
(Nobori, OFDI, Misago)¾ Misago to be launched ahead of plan (JP)(Original plan: during the fiscal year ending Mar. 2014)

 Promote key strategies in “Minimally invasive treatment” field¾ Continuously expand Interventional Cardiology business¾ Strengthen Neuro & Peripheral intervention business¾ Enhance intravascular imaging business In this 2nd Half, launch new products which generates good
momentum for the next mid-term plan
2012/10/30©Terumo Corporation

3/6

Launching New Products in “Minimally Invasive Treatment”
Strategies
Continuously expand
Interventional Cardiology
business

Mar. 2013

Mar. 2014

Mar. 2015 – Mar.
2017

Nobori（Drug Eluting Stent）
New DES

License agreement w/ Biosensors
has been extended (EU, Asia)

Therapeutic device(US)

Strengthen
Neuro & Peripheral
intervention business

Enhance
Intravascular imaging
business

FRED (EU)（Flow Diverter Stent）

JP, US

LVIS (EU)（Coil Assisting Stent）

USAZUR (JP)（Peripheral Embolization Coil)

Misago (JP)（Peripheral Stent)

US

OFDI (EU)（Intravascular Imaging）

JP

2012/10/30©Terumo Corporation

4/6

Terumo BCT Status


Sales integration¾

Production Integration and expansion¾¾

Acquired site for new factory near Ho Chi Minh City, Vietnam
Full-scale project for production integration initiatedNew products development¾



JP: Market share of automated blood collection system isapproaching 50%

New automated blood component processing systems,
TACSI (for concentrated red cells) and Reveos debuted at
American Association of Blood Banks conference(AABB)Securing its profitability and FCF higher than plannedeven under very competitive market environment
2012/10/30©Terumo Corporation

5/6

Impact of Unrest in China
Overall, minor impact on 1st Half result.
Full-year forecast expected to be achieved.

¾

Minor impact on Cardiac & Vascular business foreseen thru full year

¾Slight impacts on General Hospital and Blood Management businesses

Influence on China strategy¾Accelerate to switch from export-driven business
to “Local production for local market” business¾Measure against elevated labor cost: capital investment
for labor-saving¾

Production center for global export to be further shifted to Asia
2012/10/30©Terumo Corporation

6/6

IR Contact
Terumo Corporation
Corporate Communication (IR) Dept.
E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, the forward-looking statements
including financial projections are based upon our assumptions using information
available to us at the time and are not intended to be guarantees of future events orperformance. Accordingly, it should be noted that actual results may differ from those
forecasts on projections due to various factors. Factors affecting to actual results
include, but are not limited to, changes in economic conditions surrounding Terumo,
fluctuations of foreign exchange rates, and state of competition.
The market share information in this presentation is partly derived from our own
independent research.

2012/10/30©Terumo Corporation

7/6